C. Ding, G. Jones, Lumiracoxib (Novartis), in IDrugs, vol. 5, n. 12, dicembre 2002, pp. 1168-72, PMID12800058.
C. Rordorf, N. Kellett; S. Mair; M. Ford; S. Milosavljev; J. Branson; G. Scott, Gastroduodenal tolerability of lumiracoxib vs placebo and naproxen: a pilot endoscopic study in healthy male subjects., in Aliment Pharmacol Ther, vol. 18, n. 5, settembre 2003, pp. 533-41, PMID12950426.
E. Mysler, Lumiracoxib (Prexige): a new selective COX-2 inhibitor, in Int J Clin Pract, vol. 58, n. 6, giugno 2004, pp. 606-11, PMID15311562.
C. Atherton, J. Jones; B. McKaig; J. Bebb; R. Cunliffe; J. Burdsall; J. Brough; D. Stevenson; J. Bonner; C. Rordorf; G. Scott, Pharmacology and gastrointestinal safety of lumiracoxib, a novel cyclooxygenase-2 selective inhibitor: An integrated study, in Clin Gastroenterol Hepatol, vol. 2, n. 2, febbraio 2004, pp. 113-20, PMID15017615.
M. Bitner, J. Kattenhorn; C. Hatfield; J. Gao; D. Kellstein, Efficacy and tolerability of lumiracoxib in the treatment of primary dysmenorrhoea, in Int J Clin Pract, vol. 58, n. 4, aprile 2004, pp. 340-5, PMID15161117.
P. Geusens, R. Alten; J. Rovensky; VS. Sloan; G. Krammer; G. Kralidis; P. Richardson, Efficacy, safety and tolerability of lumiracoxib in patients with rheumatoid arthritis, in Int J Clin Pract, vol. 58, n. 11, novembre 2004, pp. 1033-41, PMID15605667.